University of PittsburghUniversity of Pittsburgh
Technologies
TechnologiesExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Fully Human Fabs to CD22 (bCAT1)

OverviewRequest InfoMore Like ThisExpress Licenses

Technology Type

Therapeutic Modality

Technology Subtype

Antibody - Fab

Therapeutic Areas

Oncology

Therapeutic Indications

LymphomaLeukemia

Lead Inventor

Dimiter Dimitrov

All Innovators

Dusan BaekDimiter Stanchev DimitrovWei LiJohn W. Mellors

Technology Readiness Level

2. Initial proof of concept, in-vitro

Date Submitted

Jan 27, 2019

Reference Number

04874

Using newly constructed antigen binding fragment (Fab) phage display libraries, Pitt researchers have identified and characterized fully human Fabs to the CD22-D7 domain, targeting the membrane-proximal immunoglobulin domain D7. These binders show nanomolar-level binding affinity to the recombinant D7 protein and specific binding to CD22-expressing lymphoma cell lines. Their sequences and binding epitopes are distinct from a highly clinically-successful monoclonal antibody, m971, previously discovered by the same lab. These binders have significant potential to be incorporated into CAR-T cells for leukemia and lymphoma treatment; in addition, these antibodies can be further developed into other therapeutic modalities, such as IgG1s, immunotoxins, and antibody drug conjugates.

Description

The cluster of differentiation-22 (CD22) is a transmembrane glycoprotein and sialic acid receptor found on most B cells that functions as an inhibitory receptor for B cell receptor (BCR) signaling, indicating its role in B cell function, survival, and apoptosis. Due to its B cell lineage-specific expression, CD22 has emerged as an ideal target for treating B cell malignancies, including most lymphomas and leukemias, and success has been demonstrated using monoclonal antibody-based therapeutics to target it. Interestingly, the efficacy of CD22-targeted mAb-based CAR-T cell therapy is shown to be critically dependent on the epitope location, with anti-CD22 mAbs targeting the most membrane-proximal domain/epitope exhibiting much higher killing activity than those targeting distal epitopes.

Applications

• Treating B cell related cancers, including most leukemias and lymphomas

Advantages

• Broadly applicable to most B cell related cancers
• High therapeutic potential in pediatric B cell cancers, in which lack of expression of cell surface targeting molecules frequently limits treatment options
• Targets the membrane proximal epitopes for maximum efficacy

Invention Readiness

In vitro data

Discover More with AI